Articles published by MannKind
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
November 07, 2024
From MannKind
Via GlobeNewswire
Tickers
MNKD
MannKind to Present at 2024 UBS Healthcare Conference
November 05, 2024
From MannKind
Via GlobeNewswire
Tickers
MNKD
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
November 04, 2024
From MannKind
Via GlobeNewswire
Tickers
MNKD
MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
October 31, 2024
From MannKind
Via GlobeNewswire
Tickers
MNKD
MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
September 10, 2024
From MannKind
Via GlobeNewswire
Tickers
MNKD
MannKind to Present at Upcoming Conferences
August 27, 2024
From MannKind
Via GlobeNewswire
Tickers
MNKD
Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board
August 14, 2024
From MannKind
Via GlobeNewswire
Tickers
MNKD
MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update
August 07, 2024
From MannKind
Via GlobeNewswire
Tickers
MNKD
MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024
July 30, 2024
From MannKind
Via GlobeNewswire
Tickers
MNKD
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
May 08, 2024
From MannKind
Via GlobeNewswire
Tickers
MNKD
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
May 01, 2024
From MannKind
Via GlobeNewswire
Tickers
MNKD
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
April 30, 2024
From MannKind
Via GlobeNewswire
Tickers
MNKD
MannKind Repays Certain Debt Obligations
April 03, 2024
From MannKind
Via GlobeNewswire
Tickers
MNKD
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
March 05, 2024
From MannKind
Via GlobeNewswire
Tickers
MNKD
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
February 27, 2024
From MannKind
Via GlobeNewswire
Tickers
MNKD
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
February 20, 2024
From MannKind
Via GlobeNewswire
Tickers
MNKD
MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
February 15, 2024
From MannKind
Via GlobeNewswire
Tickers
MNKD
MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million
January 02, 2024
From MannKind
Via GlobeNewswire
Tickers
MNKD
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.